There is two FDA-approved anti-VEGF pathway, Bevacizumab (Avastin/anti-VEGF-antibody) and Ramucirumab (Cyramza/anti-VEGFR antibody), for advanced NSCLC, which are used alone or in combination with chemotherapy. This evidence concerns the gene KDR and non-small cell lung carcinoma.